Latest Breaking News On - International society for extracellular vesicles - Page 5 : comparemela.com

Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update May 13, 2021 16:05 ET | Source: Capricor Therapeutics Capricor Therapeutics -Data for Phase II INSPIRE Clinical Trial Expected in Third Quarter- -Plan to File IND for Multivalent Exosome-mRNA Vaccine for SARS-CoV-2 in Third Quarter- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- LOS ANGELES, May 13, 2021 (GLOBE NEWSWIRE) Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, today reported its financial results for the first quarter ended March 31, 2021, and provided an overview of its recent operational highlights. Management will host a webcast and conference call at 4:30 p.m. today after market.

United statesLinda marbJohns hopkins universityCapricor therapeutics incAmerican society of geneInternational society for extracellular vesiclesRequested meetingDiscuss next stepsDuchenne muscularTrial expectedWebcast todayRecent corporate developmentsAmerican societyCell therapyInternational societyExtracellular vesicles